ALGOTX
14.3.2023 08:02:19 CET | Business Wire | Press release
European biotech AlgoTx, the developer of first-in-class treatment ATX01 for chemotherapy-induced peripheral neuropathy (CIPN), announced today the success of a €20M Series B fundraising led by Relyens Innovation Santé / Turenne Capital , followed by UI Investissement, and historical investors Bpifrance through its Innobio 2 fund and Omnes Capital. Early and new business angel investors also significantly participated in this financing round, and AlgoTx secured an additional 1M€ in non-dilutive financing. The proceeds will be used to demonstrate the clinical efficacy of ATX01 in neuropathic pain.
Bervin Bouani, Investment Director at Turenne Capital, commented: “We are very proud to lead this strategic financing round to support AlgoTx to continue the clinical development of ATX01 lead candidate that has the potential to significantly improve the lives of patients with neuropathic pain. We look forward to working with Stéphane and his outstanding team to transform AlgoTx into a global pain player.”
Following the demonstration of ATX01’s early clinical safety and low systemic passage in Phase 1, the Phase 2 “ACT” study will now assess ATX01’s ability to reduce pain in adult CIPN patients – a program granted “fast-track” designation by FDA. In parallel, the Phase 2 “EASE” study will explore ATX01’s efficacy in the debilitating pain of erythromelalgia, a program for which ATX01 was granted “Orphan Disease Designation” in the US and Europe.
Stéphane Thiroloix, Founder & CEO of AlgoTx, says: “It is incredibly exciting to start the efficacy trials of ATX01, supported by such a high-profile syndicate of investors. We look forward to enrolling patients in our studies any day now.”
Over half of cancer patients treated with chemotherapy develop CIPN and experience sensory symptoms and pain in the hands and feet: loss of sensitivity, tingling, burning, cold and intense pain can persist for months to years after treatment. It affects over two million patients in the US and Europe and represents a leading cause for modification or interruption of chemotherapy. To this date, no therapeutic approach has offered a satisfactory response for patients and their caregivers, oncologists, neurologists and pain specialists.
« We are very pleased to support the AlgoTx team in the development of ATX01, driven by our belief in its significant impact in the treatment of CIPN and other neuropathic pain. AlgoTx can truly transform the lives of patients suffering from these conditions », says Pauline de Breteuil Senior Partner UI Investissement / FCPI Majycc Innovation Santé.
About AlgoTx
AlgoTx develops novel treatments for complex pain, with lead program ATX01 in Phase 2 in chemotherapy-induced peripheral neuropathy (NCT05593614) and erythromelalgia. More information at www.algotx.com
ACT study : ATX01 for the pain of ChemoTherapy, (NCT05593614). EASE study : Efficacy of ATX01 / Study in Erythromelalgia.
ABOUT TURENNE GROUP/RELYENS INNOVATION SANTÉ
Launched in 2014, Relyens Innovation Santé is is an evergreen venture capital vehicle specializing in health innovation controlled and owned by Relyens, a mutual insurance company specializing in the risk management of health, social and medical players. Relyens is the leading French player in medical civil liability. Advised by Turenne Santé (Health Division of Turenne Group), Relyens Innovation Santé's mission is to support the growth and development phases of innovative companies in the health sector.
Turenne Group, one of the leading private equity companies in France, has been supporting entrepreneurs for 23 years in their company’s innovation, development and transfer projects. As an independent player, the Group has assets of €1.4 billion under management. Its teams, made up of 68 professionals, including 52 investors, based in Paris, Lille (Nord Capital Partenaires), Lyon, Bordeaux, Marseille, Nice and Metz, support 290 business leaders, particularly in the healthcare, hospitality, innovation, BtoB services, and in the digital and impact sectors. With more than €300m, our healthcare team (Turenne Santé) invests across the entire value creation chain for healthcare companies through various investment approaches.
For more information: www.relyens.eu/fr / www.turennecapital.com
About Bpifrance and InnoBio 2
Bpifrance is the French national investment bank: it finances businesses – at every stage of their development – through loans, guarantees, equity investments and export insurances. Bpifrance also provides extra financial services (training, consultancy) to help entrepreneurs meet their challenges (innovation, export).
InnoBio 2 is an investment fund dedicated to life sciences, managed by Bpifrance, which is also one of the LPs alongside Sanofi, Boehringer Ingelheim, Takeda, Ipsen, Servier, BMS, European Investment Fund and Pasteur Mutualité. InnoBio 2, with €203 million, aims to invest in companies developing innovative products and services, close to or in early clinical development, with the objective of bringing them until the clinical proof of concept. InnoBio 2 takes minority equity stake in companies and can lead or co-lead the investment rounds.
For more information, please visit: www.bpifrance.com – Follow us on Twitter : @bpifrance - @BpifrancePresse
About Omnes
Omnes is a leading Paris-based European investor in private equity and infrastructure. With more than €5 billion in assets under management, Omnes provides companies with the equity capital they need to grow through its four core businesses: Venture Capital, Buyout & Growth Capital, Infrastructure and Co-Investment. With more than 30 trade sales and nearly 15 IPOs in 20 years (including Themis Bioscience, Biovex, arGEN-X, Novaled and Direct Energie), Omnes Venture Capital team is a leading French player in financing innovative SMEs with dual expertise in the deep-tech and healthcare sectors. Omnes is committed to ESG issues and has set up the Omnes Foundation in aid of children’s charities. The company is also a signatory to the United Nations Principles for Responsible Investment (PRI). www.omnescapital.com
About UI Investissement
UI Investissement is an independent, specialized company in the development of unlisted French companies with €1.5 billion under management. For over 50 years, UI Investissement has been committed to work alongside the managers of growing SMEs and STIs to help them emerge as economically and sustainably successful businesses through its focus on three areas: health, agro-business, and business services.
With its expertise, UI Investissement provides support to companies in the health sector at all stages of their development and plays a central role in the ecosystem. It is through the Majycc Innovation Santé fund that UI Investissement supports entrepreneurs who aim to be the architects of tomorrow's health. The roots of Majycc Innovation Santé are deeply connected to the DNA of several private clinic groups, nursing home groups, and mutual health insurance companies, representing entrepreneurship, health and human values, respect for corporate culture, and the projects of the individuals who build them.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230314005169/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ant International Obtains Key Licenses from the Central Bank of the UAE to Support Digital Payments in the AI Era14.10.2026 16:32:00 CEST | Press release
Ant International, a leading global provider of digital payments and financial technology, has secured a Retail Payment Services and Card Schemes (Category II) (RPSCS) license and Stored Value Facilities (SVF) license from the Central Bank of the UAE (CBUAE), aligning with the UAE’s broader agenda for innovation and digital transformation in the financial sector. “The RPSCS and SVF licenses mark a crucial milestone in Ant International’s efforts to support the UAE’s fintech ecosystem, aligning with the nation’s ‘We are UAE 2031’ digitalisation and fintech strategy,” said Leiming Chen, Chief Sustainability Officer and Senior Vice President of Ant International. “In accordance with the applicable CBUAE regulatory framework, we look forward to launching AI-powered global payment and account solutions to make cross-border payments and financial management more accessible." Obtaining the RPSCS license is an important step towards Antom, a leading merchant payment and digitisation services p
International Optics and Photonics Community Invited to SPIE Photonics West 202714.10.2026 16:01:00 CEST | Press release
Thousands from around the globe will share research breakthroughs and industry innovations in optics and photonics SPIE, the international society for optics and photonics, invites the global optics and photonics community to register for SPIE Photonics West 2027, happening 30 January–4 February at the Moscone Center in San Francisco, California. The dynamic week draws 24,000 researchers, engineers, students, and business leaders from around the globe, providing technical presentations, exhibitions, and networking opportunities that fuel collaboration and real-world innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261013654749/en/ SPIE Photonics West will be held 30 January-4 February 2027 in San Francisco, California. The annual event brings together 24,000 people from the global optics and photonics community to foster collaboration and innovation. SPIE anticipates more than 4,500 presentations will be given acro
Toluna Appoints Amy Fenton as Chief Executive Officer14.10.2026 15:30:00 CEST | Press release
Appointment completes the planned succession announced on October 8, 2026. Founder Frédéric Charles Petit continues as Board member, Senior Advisor and Shareholder. Toluna, a global leader in consumer insights and market research technology, today announces the appointment of Amy Fenton as Chief Executive Officer, effective October 15, 2026. Ms. Fenton succeeds Frédéric Charles Petit, who founded Toluna and has led the company for 25 years. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014103169/en/ Amy Fenton appointed as new Chief Executive Officer, Toluna The appointment concludes the structured succession process announced on October 8, 2026, led by the Board in close consultation with Mr. Petit and supported by a leading executive search firm. Ms. Fenton brings more than 30 years of leadership experience in the insights and analytics industry. She joins Toluna from MarketCast, where she served as Chief Executive Off
BanyanGlobal Family Business Advisors Named Family Business Advisory Practice of the Year at the STEP Private Client Awards for the Fourth Time14.10.2026 15:05:00 CEST | Press release
The international recognition, also awarded to the firm in 2018, 2020 and 2021, honors Banyan's approach of pairing governance with the skills and confidence families need for long-term ownership BanyanGlobal Family Business Advisors ("Banyan") has been named Family Business Advisory Practice of the Year at the 21st annual STEP Private Client Awards, one of the most respected international honors in the private client profession. It is the fourth time Banyan has won the category, following wins in 2018, 2020 and 2021. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261013883351/en/ Kelly Greig, STEP Board Member and Dennis Jaffe, BanyanGlobal Family Business Advisors at the awards ceremony. BanyanGlobal won the Family Business Advisory Practice of the Year at the 21st Annual STEP Private Client Awards. The independent judging panel singled out Banyan's approach: "BanyanGlobal Family Business Advisors has redefined family busi
Telekom Srbija Group Expands AI Investment and Strengthens U.S. Technology Partnerships14.10.2026 15:02:00 CEST | Press release
Leading Southeast European Telecommunications and Technology Group Advances AI Innovation Through International Collaboration, Startup Investments and 5G Infrastructure. Following the October 1 agreement between Serbia and the United States to strengthen cooperation in artificial intelligence (AI), Telekom Srbija Group is expanding its AI investment and deepening relationships with leading U.S. technology companies as part of its strategy to develop the next generation digital services. As part of these efforts, Telekom Srbija Group has engaged with the U.S. State Department, Department of Commerce and Export-Import Bank to explore opportunities for technology cooperation and project financing, with the ambition of becoming a preferred regional partner for U.S. companies. “Artificial intelligence represents one of the greatest opportunities for the future of telecommunications and digital services,” said Vladimir Lučić, CEO of Telekom Srbija Group. “We have been investing in this techn
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom